IL144798A0 - Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin - Google Patents

Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin

Info

Publication number
IL144798A0
IL144798A0 IL14479800A IL14479800A IL144798A0 IL 144798 A0 IL144798 A0 IL 144798A0 IL 14479800 A IL14479800 A IL 14479800A IL 14479800 A IL14479800 A IL 14479800A IL 144798 A0 IL144798 A0 IL 144798A0
Authority
IL
Israel
Prior art keywords
heparin
gpiib
tpa
aspirin
thrombosis
Prior art date
Application number
IL14479800A
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL144798A0 publication Critical patent/IL144798A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14479800A 1999-03-11 2000-03-10 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin IL144798A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12381599P 1999-03-11 1999-03-11
PCT/US2000/006451 WO2000053264A1 (en) 1999-03-11 2000-03-10 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin

Publications (1)

Publication Number Publication Date
IL144798A0 true IL144798A0 (en) 2002-06-30

Family

ID=22411057

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14479800A IL144798A0 (en) 1999-03-11 2000-03-10 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin

Country Status (12)

Country Link
EP (1) EP1161279A1 (en)
JP (1) JP2002538226A (en)
KR (1) KR20020005614A (en)
CN (1) CN1346292A (en)
AU (1) AU766089B2 (en)
BR (1) BR0010381A (en)
CA (1) CA2361650A1 (en)
EA (1) EA200100966A1 (en)
IL (1) IL144798A0 (en)
NZ (1) NZ513217A (en)
WO (1) WO2000053264A1 (en)
ZA (1) ZA200106360B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
JP2004501913A (en) * 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー Heteroaryl-phenyl substituted factor Xa inhibitors
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
DE60217835D1 (en) 2001-02-28 2007-03-15 John H Griffin Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
SE0101932D0 (en) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
KR20100102745A (en) 2001-11-26 2010-09-24 제넨테크, 인크. Catheter composition and uses thereof
EP2982668A3 (en) 2002-12-03 2016-04-13 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
EP1679067A4 (en) * 2003-09-19 2010-04-07 Kissei Pharmaceutical Concurrent drugs
US8202999B2 (en) 2005-01-07 2012-06-19 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2008070353A2 (en) 2006-11-07 2008-06-12 Genentech, Inc. Tissue plasminogen activator variant uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012204A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Anticoagulant proteins
ATE198748T1 (en) * 1993-11-24 2001-02-15 Du Pont Pharm Co ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS FIBRINOGEN RECEPTOR ANTAGONISTS
GB2299998B (en) * 1995-03-31 1997-03-26 Hamilton Civic Hospitals Res Compositions for inhibiting thrombogenesis
US5610308A (en) * 1995-05-18 1997-03-11 Bristol-Myers Squibb Company Process for preparing intermediates for thrombin inhibitors
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
EP0946508B1 (en) * 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO1999038827A1 (en) * 1998-02-02 1999-08-05 Merck & Co., Inc. PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST
EP1061908A4 (en) * 1998-03-13 2007-01-24 Merck & Co Inc Combination therapy and composition for acute coronary ischemic syndrome and related conditions
DE19816983A1 (en) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma New bicyclic heteroaromatic amidine or nitrile compounds, used as thrombin inhibitors, antithrombotic agents or intermediates

Also Published As

Publication number Publication date
NZ513217A (en) 2003-11-28
EP1161279A1 (en) 2001-12-12
BR0010381A (en) 2002-02-05
AU3525400A (en) 2000-09-28
EA200100966A1 (en) 2002-02-28
WO2000053264A1 (en) 2000-09-14
AU766089B2 (en) 2003-10-09
JP2002538226A (en) 2002-11-12
CA2361650A1 (en) 2000-09-14
KR20020005614A (en) 2002-01-17
ZA200106360B (en) 2002-08-02
CN1346292A (en) 2002-04-24

Similar Documents

Publication Publication Date Title
IL144798A0 (en) Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
ZA200306488B (en) Benzamides and related inhibitors of factor Xa.
DE60037500D1 (en) CYANOACRYLATE INCLUDING INHIBITORS AND A TURBINE
HUP0203289A3 (en) Benzamides and related inhibitors of factor xa
MY138239A (en) Nitrogen containing heterobicycles as factor xa inhibitors
EP1140871A4 (en) Thrombin or factor xa inhibitors
FI972466A0 (en) Low molecular weight bicyclic thrombin inhibitors
YU63699A (en) Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent
NO20014858D0 (en) Use of CYP2D6 inhibitors in combination therapy
NO20002958D0 (en) Benzamidine derivatives as coagulation factor Xa inhibitors
ATE163191T1 (en) SILVER CORROSION PROTECTION AGENT I
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
IS6759A (en) New thiadiazole and oxadiazole and their use as phosphodiesterase-7 inhibitors
IS5302A (en) New amidino derivatives and their use as thrombin inhibitors
HUP0200856A3 (en) Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors
IL143987A0 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
DE60228520D1 (en) Customizable absorbent articles
IL152396A0 (en) New thiochromane derivatives derivatives and their use as thrombin inhibitors
PL352200A1 (en) Inhibitors of viia agent
DE10084241D2 (en) Medium molecular weight heparin
EE200000394A (en) New use of local anesthetics against vascular headaches
NO20030841L (en) A new specific mechanism for inhibition of platelet adhesion to collagen
SE9904483D0 (en) New use
NO20014976D0 (en) Dibenzoazulin derivatives for the treatment of thrombosis, osteoporosis and arteriosclerosis
SE9903515D0 (en) New use of molecular weight heparin